- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6823
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine? ; volume:23 ; number:1 ; day:22 ; month:2 ; year:2023 ; pages:1-6 ; date:12.2023
BMC endocrine disorders ; 23, Heft 1 (22.2.2023), 1-6, 12.2023
- Classification
-
Medizin, Gesundheit
- Creator
-
Ishay, Avraham
Shacham, Elena Chertok
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12902-023-01296-4
- URN
-
urn:nbn:de:101:1-2023042821030740857671
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ishay, Avraham
- Shacham, Elena Chertok
- SpringerLink (Online service)
Other Objects (12)
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory
Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report
Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory
Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report
Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory
Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report